Turner R A, Whipple J P, Shackleford R W
Pharmacotherapy. 1984 May-Jun;4(3):151-7. doi: 10.1002/j.1875-9114.1984.tb03341.x.
Diflunisal was compared to aspirin in a 12-week, double-blind, parallel, multicenter rheumatoid arthritis study. One hundred twenty-six (126) patients received diflunisal and 123 patients received aspirin. Both treatment groups demonstrated significant improvement from baseline in joint pain, morning stiffness, grip strength, walking time and painful and swollen joint scores. For these parameters, the only statistically significant difference between the groups was that diflunisal was more effective than aspirin for overall joint pain at week 2. The overall evaluation by patients and by investigators showed significantly better responses in those treated with diflunisal at weeks 1 and 12. Diflunisal produced significantly less gastrointestinal pain and tinnitus than aspirin. Neither drug showed unusual frequency of adverse effects as determined in the laboratory. Long-term studies using a higher-dose regimen are suggested to further define the efficacy and tolerability of diflunisal in the treatment of patients with rheumatoid arthritis.
在一项为期12周的双盲、平行、多中心类风湿性关节炎研究中，将双氟尼酸与阿司匹林进行了比较。126名患者接受双氟尼酸治疗，123名患者接受阿司匹林治疗。两个治疗组在关节疼痛、晨僵、握力、步行时间以及疼痛和肿胀关节评分方面均较基线有显著改善。对于这些参数，两组之间唯一具有统计学意义的差异是在第2周时双氟尼酸对总体关节疼痛的疗效优于阿司匹林。患者和研究者的总体评估显示，在第1周和第12周时，接受双氟尼酸治疗的患者反应明显更好。双氟尼酸产生的胃肠道疼痛和耳鸣明显少于阿司匹林。在实验室检查中，两种药物均未显示出异常的不良反应发生率。建议采用更高剂量方案进行长期研究，以进一步明确双氟尼酸治疗类风湿性关节炎患者的疗效和耐受性。
